B. Riley Securities Reiterates Buy on Arrowhead Pharma, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has reiterated its Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a price target of $55.
August 12, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities has reiterated its Buy rating on Arrowhead Pharma and maintained a price target of $55.
The reiteration of a Buy rating and maintenance of a $55 price target by B. Riley Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100